Slide 1: Second Quarter Fiscal 2026 Results
Second Quarter Fiscal 2026 Results November 6, 2025 © 2025 Haemonetics Corporation
Slide 2: Q2 Fiscal 2026 Conference Call Detail
Q2 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on Conference call speakers: November 6, 2025, and can be accessed via live webcast: Link or teleconference: Link Chris Simon The financial release, accompanying slides, and a President & CEO replay of the conferen
Slide 3: Important Information
Important Information Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historic
Slide 4: Q2 Fiscal 2026 Highlights
Q2 Fiscal 2026 Highlights Delivering earnings growth and margin expansion despite last year’s portfolio transitions • (5%) reported revenue decline; (2%) organic1 revenue decline; 9% organic ex-CSL2 revenue growth. • Gross margin up 530bps Y/Y to 59.5%; Adjusted gross margin up 380bps to 60.5%. • Op
Slide 5: Q2 Fiscal 2026 Revenue by Business Unit
Q2 Fiscal 2026 Revenue by Business Unit Revenue (in millions) Organic Reported Organic Q2 2026 Q2 2025 growth, $346 growth growth $327 (in millions) ex-CSL Plasma $125.4 $138.6 (9.5%) (10.1%) 18.6% Apheresis $56.1 $54.3 3.2% 3.9% 3.9% Whole Blood $0.4 $14.2 (97.3%) - - Blood Center $56.5 $68.5 (17.6
Slide 6: Q2 Fiscal 2026 Financial Review
Q2 Fiscal 2026 Financial Review GAAP Results: Non-GAAP Results: Q2 2026 Q2 2025 Y/Y Q2 2026 Q2 2025 Y/Y Gross Margin % 59.5% 54.2% +530bps Adjusted Gross Margin % 60.5% 56.7% +380bps Operating Margin % 17.9% 15.0% +290bps Adjusted Operating Margin % 26.7% 24.2% +250bps Net Income Margin % 11.8% 9.8%
Slide 7: Q2 Fiscal 2026 Segment Performance
Q2 Fiscal 2026 Segment Performance Plasma Q2 2026 Q2 2025 Y/Y Revenue $125.4M Performance$138.6M Highlights: (9.5%) reported; 18.6% organic ex-CSL Adjusted Operating Margin %1 34.0% 32.1% +190bps Blood Center Q2 2026 Q2 2025 Y/Y (17.6%) reported; Revenue $56.5M $68.5M 3.9% organic Adjusted Operating
Slide 8: Balance Sheet and Cash Flow Metrics
Balance Sheet and Cash Flow Metrics Cash from operations (in millions) (in millions) 9/27/25 3/29/25 FCF CapEx4 $289 Cash & cash equivalents $296 $307 $73 Working capital $351 $357 Total debt $1,225 $1,225 $129 Net debt1 $928 $918 $111 $38 $216 $23 $85 Available credit2 $749 $749 $49 $32 $89 $12 $91
Slide 9: Full Year Fiscal 2026 Guidance
Full Year Fiscal 2026 Guidance November Previous Revenue guidance by segment: 2025 • Plasma: (4 – 7%) reported; 14 -17% organic growth, ex-CSL. Revenue (Reported) (3 – 6%) (1 – 4%) • Blood Center: (17 – 19%) reported; (1) -1% organic growth. • Hospital: 4 – 7% reported; 4 – 7% organic growth. Organi
Slide 10: Appendices
Appendices © 2025 Haemonetics Corporation
Slide 11: Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates
Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates 2025 CSL US Organic Currency Acquisitions & Organic ($ millions) Q2 2026 Q2 2025 Reported growth Disposable growth, impact Divestitures1 growth Revenue2 ex-CSL Plasma $125.4 $138.6 (9.5%) 0.6% - (10.1%) (28.7%) 18.
Slide 12: Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2026 Revenue Guidance
Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2026 Revenue Guidance Plasma Blood Center Hospital Total Company Reported (4 - 7%) (17 – 19%) 4 – 7% (1 – 4%) Currency impact - 1% - 1% Acquisitions & Divestitures1 - (19%) - (4%) Organic (4 – 7%) (1) – 1% 4 – 7% (1) – 2% CSL 2025 US Disposables
Slide 13: Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Fiscal 2026 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Fiscal 2026 Financial Results Interest and Earnings Operating Operating Provision for Gross profit other Net income per diluted ($ millions) expenses income income taxes expense share Reported $194.7 $136.3 $58.5 ($7.2) $12.6 $38.7 $0.81 Amortization
Slide 14: Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Fiscal 2025 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Fiscal 2025 Financial Results Interest and Earnings Operating Operating Provision for ($ millions) Gross profit other Net income per diluted expenses income income taxes expense share Reported $187.4 $135.7 $51.7 ($7.0) $10.9 $33.8 $0.66 Amortization
Slide 15: Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Year-to-Date Fiscal 2026 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Year-to-Date Fiscal 2026 Financial Results Interest and Earnings Operating Operating Provision for ($ millions) Gross profit other Net income per diluted expenses income income taxes expense share Reported $387.0 $274.6 $112.4 ($15.9) $23.7 $72.7 $1.
Slide 16: Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Year-to-Date Fiscal 2025 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q2 Year-to-Date Fiscal 2025 Financial Results Interest and Earnings Operating Operating Provision for ($ millions) Gross profit other Net income per diluted expenses income income taxes expense share Reported $362.4 $270.9 $91.5 - $19.2 $72.2 $1.40 Amor
Slide 17: Appendix D: Reconciliation of Cash Flows
Appendix D: Reconciliation of Cash Flows ($ millions) Q2 2026 Q2 2025 FY 2026 FY 2025 Free Cash Flow Reconciliation Cash provided by operating activities $111.3 $48.8 $128.7 $21.4 Capital expenditures ($5.0) ($9.4) ($8.8) ($15.1) Additions to Haemonetics’ equipment ($17.7) ($2.5) ($29.1) ($6.8) Proc
Slide 18: Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results
Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results1 TTM 2026 TTM 2025 ($ millions) Net income Net income Reported $168.2 $123.8 Amortization of acquired intangible assets $34.5 $31.3 Amortization of fair value inventory step up $7.9 $9.2 Acquisition, Integration, transaction and
Slide 19: Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income
Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2) Q2 2026 Q2 2025 Net revenues: Plasma $125.4 $138.6 Blood Center $56.5 $68.5 Hospital $145.5 $138.4 Total net revenues $327.3 $345.5 Significant segment expenses and operating performance: Plasma Cost of g
Slide 20: Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income
Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2) Q2 2026 Q2 2025 Corporate and unallocated expenses Amortization of acquired intangible assets ($13.2) ($16.0) Acquisition, integration and divestiture related costs ($1.5) ($0.9) Restructuring and restruc